gene editing

ARK Invest added positions in Shopify, Intellia Therapeutics, and GeneDX after significant stock declines, signaling Wood's conviction in long-term potential despite near-term headwinds.

Vertex Pharmaceuticals faces cystic fibrosis revenue slowdown but eyes major growth catalysts with Casgevy gene-editing and povetacicept kidney disease therapies.

Cibus transfers gene-edited herbicide-tolerant rice traits to Interoc partner, advancing commercialization in Latin America with expectations for additional trait deliveries.

Biotech M&A surges as $300B patent cliff looms by 2030. Three gene-editing firms positioned as acquisition targets offer varying risk profiles.

Vertex's cystic fibrosis market dominance faces gene therapy competition post-patent expiration, but patent protection extends through late 2030s while diversification efforts hedge risk.

Vertex Pharmaceuticals trails broader market but boasts promising pipeline candidates in kidney disease and diabetes, positioning potential recovery.

CRISPR Therapeutics stock declined 9% following a $585.2M convertible notes offering. The gene-editing company boasts FDA-approved Casgevy therapy and $1.8B in reserves but faces steep losses.

Editas Medicine reported Q4 2025 net loss of $5.6M, down 88% YoY. Lead CRISPR therapy EDIT-401 shows >90% LDL-C reduction; IND submission expected mid-2026.

Vertex Pharmaceuticals offers profitable gene-editing exposure versus CRISPR's pipeline-dependent model. Casgevy's slow adoption and high costs make Vertex's diversified, profitable business more attractive for risk-averse investors despite lower upside potential.

Prime Medicine will present at three major biotech conferences in March 2026, including TD Cowen and Citizens Life Sciences, with webcasts available afterward.

Vertex Pharmaceuticals expands beyond cystic fibrosis dominance into gene-editing treatments for blood disorders and pain management, targeting $13.1B revenue with non-CF products generating $500M+.